Global Imatinib Drug Market Size study & Forecast, by Drug Formulation (Capsules, Tablets) by Application Type (Philadelphia Positive Chronic Myeloid Leukemia, Hyper-Eosinophilic Syndrome (HES), Myelodysplastic Syndrome (MDS), Myeloproliferative Diseases (MPD), Gastrointestinal Stromal Tumors (GIST), Others) and Regional Analysis, 2023-2030
Global Imatinib Drug Market is valued approximately USD XXX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Imatinib drug is used to treat certain types of cancer. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). Imatinib specifically targets and inhibits the activity of abnormal proteins called tyrosine kinases, which are produced by specific cancer cells. Imatinib is primarily used for the treatment of chronic myeloid leukemia (CML), a type of blood cancer characterized by the overproduction of abnormal white blood cells. It can also be prescribed for the treatment of gastrointestinal stromal tumors (GISTs), a type of tumor that occurs in the gastrointestinal tract. The Imatinib Drug market is expanding because of factors such as Increasing incidence of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs) and increase in demand for target drug therapy.
Imatinib has demonstrated remarkable success in the treatment of CML, leading to high response rates and improved long-term outcomes. Thus, Rising prevelance of chronic myeloid leukemia is driving the market growth. According to National Library of Medicine, The prevalence of chronic myeloid leukemia (CML) across the globe is 112,000 in year 2020, and it is projected to increase to 144,000 by year 2030, and 167,000 cased by year 2040 and 181,000 cases by year 2050. The rising prevelance of chronic myeloid leukemia across the globe is driving the market growth. In addition, rise in healthcare expenditure and increasing R&D activities related to imatinib drug development is creating a lucrative opportunity in the market. However, high cost of imatinib drug and availability of substitutes stifles market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Imatinib Drug Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in year 2022 owing to presence of key market players, rising development of drug, rising prevelance of cancer disease in the region. Whereas Asia Pacific is witnessing a significant growth owing to factors such as rising prevelance of cancer in the region, rising investment in drug discovery activities, rising government initiatives for promoting drug development activities.
Major market player included in this report are:Sun Pharmaceutical Industries Ltd.
Novartis AG
Dr. Reddy’s Laboratories Ltd
Teva Pharmaceutical Industries Ltd.
Mylan N.V.
Cipla Inc
Apotex Inc
Sanofi S.A
Glenmark Pharmaceuticals Ltd.
Dongbao Pharmaceutical Co. Ltd.
Recent Developments in the Market:In October 2021, Tenax Therapeutics, Inc. announced that the FDA has reviewed and cleared its Investigational New Drug (IND) application for a novel formulation of imatinib.
Global Imatinib Drug Market Report Scope:Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Drug Formulation, Application Type, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Drug Formulation offerings of key players.
The detailed segments and sub-segment of the market are explained below:By Drug Formulation:
Capsules
Tablets
By Application Type:
Philadelphia Positive Chronic Myeloid Leukemia
Hyper-Eosinophilic Syndrome (HES)
Myelodysplastic Syndrome (MDS)
Myeloproliferative Diseases (MPD)
Gastrointestinal Stromal Tumors (GIST)
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa
Companies MentionedSun Pharmaceutical Industries Ltd.
Novartis AG
Dr. Reddy’s Laboratories Ltd
Teva Pharmaceutical Industries Ltd.
Mylan N.V.
Cipla Inc
Apotex Inc
Sanofi S.A
Glenmark Pharmaceuticals Ltd.
Dongbao Pharmaceutical Co. Ltd.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.